Women In Breast Cancer 2022 Volume Ii Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Women In Breast Cancer 2022 Volume Ii book. This book definitely worth reading, it is an incredibly well-written.
We are delighted to present the Frontiers in Oncology "Women in Breast Cancer” Volume II series of article collections. At present, less than 30% of researchers worldwide are women. Long-standing biases and gender stereotypes are discouraging girls and women away from science-related fields, and STEM research in particular. Science and gender equality are, however, essential to ensure sustainable development as highlighted by UNESCO. In order to change traditional mindsets, gender equality must be promoted, stereotypes defeated, and girls and women should be encouraged to pursue STEM careers.
"Providing comprehensive, current, and reliable information on breast cancer, this book, written by an experienced oncologist, a surgeon, and a breast cancer survivor, informs and inspires readers, wherever they are in the breast cancer experience. Patient stories, essays from medical specialists, and illustrations add clarity and insight"--
Uniquely designed for oncologists and general practitioners, this book offers clinicians comprehensive guidelines when dealing with women at high risk for breast cancer. Written by experts in the field on the cutting edge of this research, the following questions will be answered for the reader by the end of the book: · Who is at elevated risk for breast cancer? · Who should be genetically screened? · When and how often should we obtain imaging? · What type of imaging is adequate? · What medications are available for prevention? · When is surgical intervention appropriate? · What lifestyle changes should be implemented to prevent this disaster? With one in eight women likely to contract breast cancer in her lifetime, the significance of identifying and managing the high-risk patient is evident. Breakthroughs in the identification of genes associated with breast carcinoma, particularly BRCA1 and 2, as well as other risk factors, influence not only how patients are screened, but also how they are treated. Breast Cancer Prevention and Treatment provides a guided approach to prevention of breast cancer in women at elevated risk for this malignancy.
Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free. Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers. Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a "compassionate use" program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science.
Addresses the emotional and psychological challenges of fighting breastancer, refutes popular assumptions about treatment and post-treatmentptions, and offers guidance for making health decisions.